Disrupted in renal carcinoma 3 (DIRC3)

Disrupted in renal carcinoma 3 (DIRC3) is a nuclear long non-coding RNA that regulates transcription by modulating local chromatin architecture; it activates the adjacent tumor suppressor gene IGFBP5 and inhibits occupancy of the SOX10 transcription factor in key cancer-associated regulatory regions. DIRC3 loss leads to increased anchorage-independent growth—a hallmark of malignancy—and more aggressive phenotypes in melanoma, thyroid, and head and neck cancers. Its expression is a biomarker of better prognosis, and specific genetic variants within DIRC3 further influence cancer outcomes. No drug modulators are currently documented, but it is considered a promising candidate for future epigenetic or RNA-targeted therapies.

Other names

FLJ14199DIRC3

For modulation as a therapeutic target, the mechanism involves: Enhancement of DIRC3 expression to activate IGFBP5 and suppress malignant transformation; Epigenetic modification/local chromatin structure inhibition of SOX10 occupancy; Suppression of IGF1/Akt pathway signaling (in thyroid cancer)